The medical journal Lancet is reporting a study on an amazing new Ebola vaccine. The recombinant, replication-competent vesicular stomatitis virus-based vaccine was used in studies in Guinea, West Africa between April 1, 2015, and July 20, 2015.
There were a total of 90 clusters with a total population of 7651 people that were included in the planned interim analysis. 48 of these clusters (4123 people) were randomly assigned to immediate vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly assigned to delayed vaccination with rVSV-ZEBOV.
In the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomisation, whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine efficacy of 100%
WHO is calling this a game-changer! I would say so!